Cameron Santoro is an associate editor for The Center for Biosimilars®, The American Journal of Managed Care® (AJMC), and AJMC.com.
Assays Reveal Equivalence Between Adalimumab-aqvh and Humira
Comprehensive assay research concluded similar structures, functions, and stability between reference adalimumab (Humira) and adalimumab-aqvh.
The Top 5 Biosimilar Articles for the Week of December 11
Here are the top 5 biosimilar articles for the week of December 11, 2023.
Study Shows Similar Efficacy, Drug Survival Rates for Etanercept Biosimilar vs Originator in RA
A national study on patients with rheumatoid arthritis (RA) compares the disease activity and drug survival rate between an etanercept biosimilar and the originator (Enbrel).
The Top 5 Biosimilar Articles for the Week of December 4
Here are the top 5 biosimilar articles for the week of December 4, 2023.
Adalimumab Biosimilar GP2017 Shows Similar Safety, Efficacy to Originator in Patients With IBD
Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.
The Top 5 Biosimilar Articles for the Week of November 27
Here are the top 5 biosimilar articles for the week of November 27, 2023.
The Top 5 Biosimilar Articles for the Week of November 20
Here are the top 5 biosimilar articles for the week of November 20, 2023.
Study Confirms Safety and Efficacy of Adalimumab Biosimilar HS016 in IBD
A China-based study where data were collected from patients with inflammatory bowel disease (IBD) showed safety and efficacy of the adalimumab biosimilar HS016.